title: Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test.
abstract: Hypersensitivity reactions are a classic side effect of cetuximab. We report the cases of three patients who developed life-threatening hypersensitivity to cetuximab, which could have been predicted by assessing the concentration of serum anticetuximab immunoglobulin (Ig)E. The anticetuximab IgE concentration could be an interesting test to predict which patients are at risk of experiencing severe hypersensitivity reactions to cetuximab.
authors.affiliation: CHU de Caen, Service d'Hépato-Gastroentérologie et Nutrition, Caen, France. ; Université de Caen Basse-Normandie, UFR Médecine, Caen, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Dupont
authors.affiliation: CHU de Caen, Laboratoire d'Immunologie et Immunopathologie, Caen, France.
authors.forename: Delphine
authors.initials: D
authors.lastname: Mariotte
authors.affiliation: Centre Henri Becquerel; Oncologie Médicale, Rouen, France.
authors.forename: Cristian
authors.initials: C
authors.lastname: Moldovan
authors.affiliation: Centre François Baclesse, Service de Recherche Clinique, Caen, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Grellard
authors.affiliation: CHU de Caen; Service de Médecine Polyvalente, Caen, France.
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Vergnaud
authors.affiliation: Université de Caen Basse-Normandie, UFR Médecine, Caen, France. ; CHU de Caen, Laboratoire d'Hormonologie, Caen, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Laroche
authors.affiliation: Centre François Baclesse, Oncologie Médicale, Caen, France.
authors.forename: Radj
authors.initials: R
authors.lastname: Gervais
keywords: anaphylaxis; antidrug IgE; cetuximab; hypersensitivity; neoplasms
references.citation: J Oncol Pharm Pract. 2013 Jun;19(2):130-7
references.pmid: 23154574
references.citation: Clin Colorectal Cancer. 2010 Oct;9(4):224-8
references.pmid: 20920994
references.citation: Oncology (Williston Park). 2006 Oct;20(11):1373-82; discussion 1382, 1392-4, 1397
references.pmid: 17112000
references.citation: MAbs. 2011 Jul-Aug;3(4):396-401
references.pmid: 21654207
references.citation: J Oncol Pharm Pract. 2013 Sep;19(3):222-7
references.pmid: 23135806
references.citation: N Engl J Med. 2008 Sep 11;359(11):1116-27
references.pmid: 18784101
references.citation: N Engl J Med. 2008 Mar 13;358(11):1109-17
references.pmid: 18337601
references.citation: J Clin Oncol. 2011 Aug 10;29(23):e680-1
references.pmid: 21690469
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3644-8
references.pmid: 17704414
references.citation: J Clin Oncol. 2012 Jan 20;30(3):334; author reply 335
references.pmid: 22162592
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544
references.citation: Lancet. 2009 May 2;373(9674):1525-31
references.pmid: 19410716